| Duke University | |
|---|---|
| Location | Durham, NC, USA |
| Type | Private Research University |
| Founded | 1838 |
| Website | https://duke.edu/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Neuroinflammation](/mechanisms/neuroinflammation), [Clinical Trials](/clinical-trials) |
| Departments | Department of Neurology, Department of Neuroscience, Center for Aging and Human Development |
| Notable Centers | Bryan Alzheimer's Disease Research Center, Duke Movement Disorders Clinic, Duke-UNC Brain Aging Research Center |
Duke University is a premier private research institution located in Durham, NC, USA[1]. The institution has established itself as a major force in neurodegenerative disease research through its Department of Neurology, Department of Neuroscience, and specialized research centers. Duke's neurodegeneration research programs span Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), and related conditions.
Duke University hosts numerous researchers tracked in the NeuroWiki database and maintains multiple departments and centers dedicated to neuroscience and aging research[2]. The institution's research programs combine basic science investigation with clinical translation, advancing understanding of disease mechanisms, biomarkers, and therapeutic interventions.
With over $1.5 billion in annual research funding, Duke ranks among the nation's top research universities. The Medical Center, which includes the School of Medicine and Duke University Health System, provides an integrated environment for translating basic science discoveries into clinical applications.
Duke University was founded in 1838 as Brown's Schoolhouse, a small school in Randolph County, North Carolina. The institution moved to Durham in 1892 and was renamed Trinity College before becoming Duke University in 1924 following a significant endowment from Washington Duke.
The Bryan Alzheimer's Disease Research Center was established in 1985 as one of the original NIA-funded ADRCs[3]. This center has been instrumental in advancing understanding of Alzheimer's disease and related dementias. Over its four decades of operation, the Bryan ADRC has enrolled thousands of participants in longitudinal studies and clinical trials.
The Department of Neurology has grown from a small academic unit to one of the nation's leading neurology programs. Key milestones include:
The Bryan ADRC is one of the original NIA-funded Alzheimer's Disease Research Centers, established in 1985. The center focuses on:
The center maintains one of the largest and most well-characterized longitudinal cohorts of participants, with comprehensive clinical, cognitive, imaging, and biomarker data. This resource has enabled numerous landmark studies on disease progression and risk factors.
The Movement Disorders program at Duke is a leader in Parkinson's disease research and treatment:
Duke is home to advanced neuroimaging capabilities:
The neuroimaging core provides state-of-the-art scanning capabilities for both research and clinical studies, supporting the center's extensive portfolio of imaging studies.
Duke researchers investigate the critical role of neuroinflammation in neurodegenerative diseases:
The neuroinflammation program at Duke is one of the most comprehensive in the country, spanning basic science investigations to clinical trials of immunomodulatory therapies.
Duke's biomarker research includes:
Duke actively participates in clinical trials for:
| Researcher | H-index | Focus Areas |
|---|---|---|
| Warren Strittmatter | 75 | Alzheimer's Disease, Amyloid, APP[12:1] |
| Michael Lutz | 45 | Neuroinflammation, Microglia, TREM2[9:1] |
| John Ervin | 40 | Movement Disorders, Parkinson's Disease[15] |
| Jeffrey Covey | 35 | Cognitive Disorders, Clinical Trials |
Dr. Warren Strittmatter's laboratory has made seminal contributions to understanding Alzheimer's disease pathogenesis. His work on apolipoprotein E and its role in amyloid deposition established new paradigms in AD research. Current research focuses on:
Dr. Michael Lutz leads one of the premier neuroinflammation programs in the country. His work on TREM2 and microglial biology has illuminated the role of innate immunity in neurodegeneration. Current projects include:
Led by Dr. John Ervin, Duke's Movement Disorders program provides comprehensive care for patients with Parkinson's disease and related disorders. The program combines clinical excellence with cutting-edge research in:
Duke actively recruits for neurodegenerative disease clinical trials. Current studies include:
Contact: Duke Clinical Research Unit — clinicaltrials@duke.edu
Duke maintains active collaborations with:
The Research Triangle of North Carolina, comprising Duke, UNC-Chapel Hill, and NC State University, provides a unique environment for interdisciplinary collaboration. The Duke-UNC Brain Aging Research Center represents a particularly strong partnership, combining the expertise of both institutions in aging and neurodegeneration research.
Duke researchers maintain substantial grant funding from multiple sources:
Duke's neuroscience and neurology programs consistently rank among the top in the United States:
Duke maintains state-of-the-art research facilities for neurodegenerative disease research:
The Duke Clinical Research Unit coordinates all clinical trials in neurodegeneration, providing:
Duke maintains extensive biorepositories supporting neurodegenerative disease research:
Duke offers comprehensive training in neurodegenerative disease research:
Duke's training programs have produced numerous leaders in the field:
Duke's future research priorities include:
TREM2 Biology: Building on foundational discoveries about TREM2 variants and AD risk, Duke investigators are developing TREM2-targeting therapeutics and studying microglial activation in detail[9:2].
Alpha-Synuclein Therapeutics: Duke is leading efforts to develop disease-modifying therapies for Parkinson's disease, including immunotherapy and small molecule approaches.
Vascular Contributions: Understanding the intersection between cerebrovascular disease and neurodegeneration is a growing focus, with implications for both understanding disease mechanisms and developing prevention strategies[18].
Digital Phenotyping: Duke is at the forefront of integrating digital health technologies into neurodegeneration research, including smartphone-based assessments and wearable sensors.
Duke Neurology Research. 2026. ↩︎
Bryan ADRC Annual Report. 1985. ↩︎
Blennow K, et al. Biomarkers for Alzheimer's disease: status and future needs. Lancet Neurol. 2019. ↩︎
Donti M, et al. Deep brain stimulation for Parkinson's disease. Mov Disord. 2021. ↩︎
Goldman JS, et al. Genetic forms of Parkinson's disease. Nat Rev Neurol. 2019. ↩︎ ↩︎
Rabinovici GD, et al. Association of amyloid PET with clinical outcomes in amyloid-positive patients. JAMA Neurol. 2017. ↩︎
Chen Y, et al. Neuroinflammation in neurodegenerative disease. Nat Rev Neurosci. 2019. ↩︎
Chen X, et al. TREM2 regulates microglial function and amyloid clearance. Nat Rev Neurol. 2018. ↩︎ ↩︎ ↩︎
Martinez ES, et al. Complement system in neurodegenerative diseases. Nat Rev Neurol. 2019. ↩︎
Schindler SE, et al. Cerebrospinal fluid biomarkers in Alzheimer's disease. Continuum. 2019. ↩︎
Strittmatter WJ, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and localization to gene loci in Alzheimer's disease. Proc Natl Acad Sci USA. 1996. ↩︎ ↩︎
Pang H, et al. Amyloid-targeting immunotherapy for Alzheimer's disease. Nat Rev Drug Discov. 2019. ↩︎ ↩︎
Parsons CG, et al. Memantine: a NMDA receptor antagonist for Alzheimer's disease. Expert Opin Pharmacother. 2013. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Poltis M, et al. Neuroimaging in Parkinson's disease: from neuroscience to clinical practice. Lancet Neurol. 2015. ↩︎
Jack CR Jr, et al. NIA-AA research framework: towards a biological definition of Alzheimer's disease. Alzheimers Dement. 2018. ↩︎
Jorgensen NW, et al. Cardiovascular disease and risk of cognitive decline. Neurology. 2019. ↩︎